Evaluation of the Ginsburg Scheme: Where Is Significant Prostate Cancer Missed?

Evaluation of the Ginsburg Scheme: Where Is Significant Prostate Cancer Missed?

Background: Systematic biopsy (SB) according to the Ginsburg scheme (GBS) is widely used to complement MRI-targeted biopsy (MR-TB) for optimizing the diagnosis of clinically significant prostate cancer (sPCa). Knowledge of the GBS’s blind sectors where sPCa is missed is crucial to improve biopsy str...

Full description

Bibliographic Details
Main Authors: August Sigle, Cordula A. Jilg, Timur H. Kuru, Nadine Binder, Jakob Michaelis, Markus Grabbert, Wolfgang Schultze-Seemann, Arkadiusz Miernik, Christian Gratzke, Matthias Benndorf, Rodrigo Suarez-Ibarrola
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
prostatic neoplasms [MeSH]
image-guided biopsy [MeSH]
fusion biopsy
Ginsburg scheme
biopsy strategy
Online Access:https://www.mdpi.com/2072-6694/13/10/2502

Internet

https://www.mdpi.com/2072-6694/13/10/2502

Similar Items